Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Idasanutlin - Roche

Next Previous
X
Search
Drug Profile

Idasanutlin - Roche

Alternative Names: RG-7388; RO-5503781

Latest Information Update: 24 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Roche
  • Developer Mayo Clinic; National Cancer Institute (USA); NHS Greater Glasgow and Clyde; Roche; University of Glasgow
  • Class Aminobenzoic acids; Antineoplastics; Halogenated hydrocarbons; Pyrrolidines; Small molecules
  • Mechanism of Action Proto-oncogene protein c-mdm2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Cancer; Diffuse large B cell lymphoma; Essential thrombocythaemia; Follicular lymphoma; Glioblastoma; Multiple myeloma; Neuroblastoma; Non-Hodgkin's lymphoma; Polycythaemia vera; Precursor cell lymphoblastic leukaemia-lymphoma; Prostate cancer; Rhabdoid tumour; Solid tumours

Most Recent Events

  • 24 Jul 2024 Discontinued - Phase-I/II clinical trials in Precursor cell lymphoblastic leukaemia-lymphoma (In adolescents, In children, In infants, In neonates, Second-line therapy or greater, In adults, Monotherapy) in USA, United Kingdom, Spain, Netherlands, France, Canada (PO) (NCT04029688)
  • 24 Jul 2024 Discontinued - Phase-I/II clinical trials in Solid tumours (Second-line therapy or greater, In adults, In children, In adolescents, In infants, In neonates, Combination therapy) in Netherlands, France, Spain, Canada, USA, United Kingdom (PO) (NCT04029688)
  • 24 Jul 2024 Discontinued - Phase-I/II for Acute myeloid leukaemia (In adults, Second-line therapy or greater, In adolescents, Monotherapy, In neonates, In infants, In children) in France, Spain, Netherlands, Canada, US and the United Kingdom (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top